GlassScriptPhysician profile
Denver G Brown
NPI 1508235557
$7,263.91
in general payments reported to CMS, 2019-2025
37 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,420 · 2022: $1,322 · 2023: $1,356 · 2024: $1,041 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,365.91 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,334.76 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $622.99 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $541.62 | 2021-2023 | Xarelto |
| Abbvie INC. | $530.66 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $401.31 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Amarin Pharma, INC. | $208.00 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.86 | 2024-2025 | Caplyta |
| Abbott Laboratories | $185.49 | 2021-2025 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.07 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $174.67 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.83 | 2021-2025 | Jardiance |
| Lundbeck LLC | $119.94 | 2021-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $118.33 | 2021-2023 | |
| Glaxosmithkline, LLC. | $109.13 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denver Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.